Drug discovery services company makes the Financial Times’ top 1000 list

Privately-owned drug discovery services company, Domainex, has been included in the annual top 1000 list of Europe’s fastest growing companies, published by the Financial Times.

The annual FT 1000 is a list of companies from 31 European countries (across all sectors) that have achieved the highest compound annual growth rate in revenue between 2013 and 2016.

“We are delighted to appear in the 2018 FT 1000 listing: our growth over the last 3 years has been achieved entirely organically,” commented Tom Mander, COO for Domainex. “This reflects our sustained efforts to provide innovative and high quality services to an increasing number of customers including pharmaceutical, biotechnology and academic organisations from around the world. This achievement has only been possible thanks to the hard work and dedication of our staff, over 70% of whom are PhD qualified. Their commitment enables us to deliver value-generating results for our clients in their quest for optimised drug candidates that will ultimately improve the lives of patients. I would like to thank each and every one of them, our investors and of course all of our loyal and valued customers, for their continued support.”

“Our aim is to significantly increase the speed from drug target to candidate molecule for our clients,” added Trevor Perrior, CSO for Domainex. “We are proud of our track record of delivery on their behalf. Domainex has come a long way since it was established in 2001 and we are looking ahead with even greater ambition.”